Efficacy and safety of Qingre Lishi decoction for type 2 diabetes: a systematic review and meta-analysis
Abstract
Objective: This systematic review and meta-analysis aimed to evaluate the efficacy and safety of Qingre Lishi decoction (QRLSD) for type 2 diabetes (T2D), thereby providing new evidence-based insights into the role of traditional Chinese medicine in treating T2D.
Methods: WanFang, Embase, Web of Science, PubMed, China National Knowledge Infrastructure, and the Cochrane Library were searched up to January 2025. Studies assessing the efficacy and safety of QRLSD in treating T2D were included. Data were pooled using standardized mean difference (SMD) and risk ratio (RR). Sensitivity and subgroup analyses were performed to assess the stability of the results and investigate potential sources of heterogeneity. Statistical analyses were conducted using RevMan 5.4 and Stata 18.0.
Results: A total of 18 randomized controlled trials (RCTs) were included. Our results showed that QRLSD reduced the levels of fasting blood glucose (SMD: -15.09; 95% CI: [-18.27, -11.90], I² = 99%, P < 0.00001), 2-hour postprandial blood glucose (SMD: -17.71; 95% CI: [-21.70, -13.71], I² = 98%, P < 0.00001), glycated hemoglobin (SMD: -18.93; 95% CI: [-22.77, -15.09], I² = 98%, P < 0.00001), as well as other metabolic parameters, indicators of insulin resistance, and body mass index. No significant difference in the incidence of adverse events between the intervention and control groups was found (RR: 1.8; 95% CI: [0.57, 5.68], I² = 9%, P=0.32).
Conclusion: For T2D, QRLSD can significantly improve clinical…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.